Home Cart 0 Sign in  

[ CAS No. 61032-42-6 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 61032-42-6
Chemical Structure| 61032-42-6
Structure of 61032-42-6 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 61032-42-6 ]

Related Doc. of [ 61032-42-6 ]

Alternatived Products of [ 61032-42-6 ]

Product Details of [ 61032-42-6 ]

CAS No. :61032-42-6 MDL No. :MFCD16620533
Formula : C16H17NO4 Boiling Point : -
Linear Structure Formula :- InChI Key :CKHQUPXMMAOBTC-UHFFFAOYSA-N
M.W : 287.31 Pubchem ID :11098159
Synonyms :

Calculated chemistry of [ 61032-42-6 ]

Physicochemical Properties

Num. heavy atoms : 21
Num. arom. heavy atoms : 12
Fraction Csp3 : 0.19
Num. rotatable bonds : 6
Num. H-bond acceptors : 4.0
Num. H-bond donors : 1.0
Molar Refractivity : 79.6
TPSA : 70.78 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : Yes
CYP2C9 inhibitor : Yes
CYP2D6 inhibitor : Yes
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.87 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.92
Log Po/w (XLOGP3) : 3.08
Log Po/w (WLOGP) : 2.5
Log Po/w (MLOGP) : 2.16
Log Po/w (SILICOS-IT) : 2.63
Consensus Log Po/w : 2.66

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.59
Solubility : 0.0741 mg/ml ; 0.000258 mol/l
Class : Soluble
Log S (Ali) : -4.23
Solubility : 0.0168 mg/ml ; 0.0000584 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -4.9
Solubility : 0.00363 mg/ml ; 0.0000126 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 0.0
Synthetic accessibility : 2.43

Safety of [ 61032-42-6 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 61032-42-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 61032-42-6 ]
  • Downstream synthetic route of [ 61032-42-6 ]

[ 61032-42-6 ] Synthesis Path-Upstream   1~13

  • 1
  • [ 61032-41-5 ]
  • [ 61032-42-6 ]
YieldReaction ConditionsOperation in experiment
99.4% With iron; ammonium chloride In methanol; water at 80℃; for 0.5 h; Inert atmosphere 8.0 g of compound II, 12.0 g of iron powder, 12.0 g of ammonium chloride, 60 ml of water, 120 ml of methylene chlorideThe mixture of alcohols was stirred at 80 ° C for 30 minutes under reflux. TLC analysis showed no starting material and was filtered off with 50 ml of methanol and50 ml of ethyl acetate, the filtrate was spin-dried, the solvent was added to 300 ml of water,Liter of ethyl acetate and the organic phase was washed with saturated sodium chloride solution, dried over anhydrous magnesium sulfate,Dried to give 7.2 g of a brown solid (Compound 3) in 99.4percent yield;
87% With hydrogen In 1,2-dimethoxyethane at 20℃; for 7 h; Example 6 (Synthesis of methyl 2-amino-4-benzyloxy-5-methoxybenzoate); Into a glass vessel having an internal volume of 20 ml and equipped with a stirrer, a thermometer, a reflux condenser, and a balloon filled with hydrogen gas were placed 4.0 g (12.6 mmol) of methyl 4-benzyloxy-5-methoxy-2-nitrobenzoate, 0.2 g of 3percent by mass platinum sulfided carbon powder (60percent moisture content) (manufactured by N.E. CHEMCAT CORPORATION), and 20 ml of dimethoxyethane, and the resultant mixture was reacted in a hydrogen gas atmosphere at room temperature for 7 hours with stirring. After completion of the reaction, the reaction mixture was allowed to stand for 10 days and then filtered, and the reaction mixture was concentrated under reduced pressure to obtain 3.17 g of methyl 2-amino-4-benzyloxy-5-methoxybenzoate as a pale brown solid (isolation yield: 87percent). Values of physical properties for the obtained methyl 2-amino-4-benzyloxy-5-methoxybenzoate are as follows. 1 H-NMR(CDCl3 , δ(ppm)); 3.81(3H,s), 3.83(3H,s), 5.09(2H,s), 5.37(2H,brs), 6.15(1H,s), 7.31-7.41(6H,m) CI-MS(m/e); 287(M+)
85%
Stage #1: With iron In ethanol; water for 3 h; Heating / reflux
Stage #2: With sodium hydroxide In ethanol; water at 20℃;
Step 2c.
Methyl 2-amino-4-(benzyloxy)-5-methoxybenzoate (Compound 204)
A mixture of compound 203 (10 g, crude), iron powder (54 g, 0.96 mol), ethanol (100 mL), and H2O (20 mL) was stirred and heated to reflux for 3 hours.
The mixture was cooled to room temperature and neutralized with aqueous sodium hydroxide (10percent).
The reaction was filtered and the filtrate was concentrated to give a residue which was extracted with dichloromethane (200 mL*2).
The combined organic layer was washed with brine and dried over MgSO4, filtered and concentrated to yield the title compound 204 as a grey solid (14.5 g, 85percent): LCMS: 288 [M+1]+.
84.7% With acetic acid; zinc In methanol; water for 3 h; Reflux A mixture of compound 5 (2.0g, 6.2mmol), zinc powder (1.2g, 19mmol), glacial acetic acid (3.6mL, 63.3mmol) in methanol: H2O (33: 3mL) was stirred at reflux for 3h. The reaction mixture was filtered while hot and the solid was washed with CH3OH. The solvent was removed from filtrate and the resulting solid was diluted with water (50mL) and subsequently extracted with ethyl acetate. The extracts were combined, washed with saturated sodium bicarbonate and saturated saline solution, and dried over anhydrous Na2SO4. The solvent was removed under vacuum to give 6 as a light yellow solid (84.7percent). Mp: 131–133°C; 1H NMR (CDCl3, 300MHz): δ (ppm) 3.83–3.84 (d, J=3.7Hz, 6H), 5.14 (s, 2H), 5.52 (s, 2H), 6.16 (s, 1H), 7.26–7.42 (m, 6H).
84.7% at 20℃; for 3 h; Reflux A solution of methyl 2-nitro-4-benzyloxy-5-methoxybenzoate (6.2 mmol, 2.0 g) was added to a 100 ml reaction flask followed by MeOH / H2(63 mmol, 3.6 ml) was slowly added dropwise, and the mixture was heated under reflux for 3 hours. The resulting mixture was stirred for 3 hours at room temperature, followed by addition of zinc powder (19 mmol, 1.2 g).After completion of the reaction, the residue was filtered off, the methanol was removed from the filtrate, and then 50 ml of water was added thereto. The mixture was extracted with ethyl acetate (30 ml x 2), and the organic phase was separated and washed successively with saturated sodium hydrogencarbonate X 2) and saturated sodium chloride (30 ml x 2). The organic layer was dried over anhydrous sodium sulfate, filtered and the filtrate was dried to give 1.5 g of 2-amino-4- benzyloxy-5-methoxybenzoate, yieldpercent 84.7,
81% With iron; ammonium chloride In methanol; water at 105℃; A suspension of 120 (495 g, 1.56 mol), Fe (305.7 g, 5.46 mol) and NH4Cl (337.0 g, 6.24 mol) in a mixture of methanol/H2O (1500 mL/500 mL) was stirred at 105° C. overnight. The mixture was cooled to room temperature, diluted with ethyl acetate (1500 mL), stirred for 3 h at room temperature and filtered. The filtrate was washed with water (500 mL×3) and brine (500 mL×3), then dried over Na2SO4. The solution was concentrated in vacuum to give 121 (363.8 g, yield=81percent) as a light brown solid
67% With iron; acetic acid In methanol for 4 h; Heating / reflux Iron powder (46.2 g, 0.828 mol) is added to a suspension of methyl A- (benzyloxy)-5-methoxy-2-nitrobenzoate (52.5g, 165.6 mmol) in acetic acid (95 ml) and MeOH (200 ml). The reaction is then heated to reflux for 4 hours. The hot reaction mixture is then filtered through diatomaceous earth with 10percent MeOH/CH2Cl2. The filtrate is concentrated in vacuo, dissolved in EtOAc, and passed through hydrous magnesium silicate using EtOAc. The organic phase is concentrated in vacuo and triturated with 30percent EtOAc/Hexane to provide methyl 2-amino-4-(benzyloxy)-5-methoxybenzoate (31.94 g, 67percent).

Reference: [1] Patent: CN105541736, 2016, A, . Location in patent: Paragraph 0044; 0047
[2] Organic Letters, 1999, vol. 1, # 11, p. 1835 - 1837
[3] Chemical Communications, 2016, vol. 52, # 87, p. 12869 - 12872
[4] Patent: EP2123627, 2009, A1, . Location in patent: Page/Page column 6-7
[5] Patent: US2009/76044, 2009, A1, . Location in patent: Page/Page column 26-27
[6] European Journal of Medicinal Chemistry, 2017, vol. 125, p. 245 - 254
[7] Patent: CN105884699, 2016, A, . Location in patent: Paragraph 0058; 0059
[8] MedChemComm, 2017, vol. 8, # 5, p. 1069 - 1092
[9] Patent: US2014/235634, 2014, A1, . Location in patent: Paragraph 0390; 0393
[10] ChemMedChem, 2016, vol. 11, # 20, p. 2327 - 2338
[11] Patent: WO2008/109613, 2008, A1, . Location in patent: Page/Page column 214
[12] Patent: WO2010/85747, 2010, A1, . Location in patent: Page/Page column 53
[13] Patent: US2007/208164, 2007, A1, . Location in patent: Page/Page column 14-15
[14] Tetrahedron Letters, 2011, vol. 52, # 10, p. 1053 - 1056
[15] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 18, p. 5342 - 5346
[16] Patent: WO2006/117552, 2006, A1, . Location in patent: Page/Page column 64-65
  • 2
  • [ 56441-97-5 ]
  • [ 61032-42-6 ]
Reference: [1] Organic Letters, 1999, vol. 1, # 11, p. 1835 - 1837
[2] Tetrahedron Letters, 2011, vol. 52, # 10, p. 1053 - 1056
[3] Patent: US2014/235634, 2014, A1,
[4] European Journal of Medicinal Chemistry, 2017, vol. 125, p. 245 - 254
[5] Patent: CN105541736, 2016, A,
[6] Chemical Communications, 2016, vol. 52, # 87, p. 12869 - 12872
[7] Patent: CN105884699, 2016, A,
[8] MedChemComm, 2017, vol. 8, # 5, p. 1069 - 1092
[9] Patent: WO2006/117552, 2006, A1,
  • 3
  • [ 1486-53-9 ]
  • [ 61032-42-6 ]
Reference: [1] Organic Letters, 1999, vol. 1, # 11, p. 1835 - 1837
[2] European Journal of Medicinal Chemistry, 2017, vol. 125, p. 245 - 254
[3] Patent: CN105884699, 2016, A,
  • 4
  • [ 3943-74-6 ]
  • [ 61032-42-6 ]
Reference: [1] Tetrahedron Letters, 2011, vol. 52, # 10, p. 1053 - 1056
[2] Patent: US2014/235634, 2014, A1,
[3] Patent: CN105541736, 2016, A,
[4] ChemMedChem, 2016, vol. 11, # 20, p. 2327 - 2338
[5] MedChemComm, 2017, vol. 8, # 5, p. 1069 - 1092
[6] Patent: WO2006/117552, 2006, A1,
  • 5
  • [ 100-39-0 ]
  • [ 61032-42-6 ]
Reference: [1] Tetrahedron Letters, 2011, vol. 52, # 10, p. 1053 - 1056
[2] MedChemComm, 2017, vol. 8, # 5, p. 1069 - 1092
[3] Patent: WO2006/117552, 2006, A1,
  • 6
  • [ 100-44-7 ]
  • [ 61032-42-6 ]
Reference: [1] Patent: US2014/235634, 2014, A1,
[2] European Journal of Medicinal Chemistry, 2017, vol. 125, p. 245 - 254
[3] Patent: CN105541736, 2016, A,
[4] Patent: CN105884699, 2016, A,
  • 7
  • [ 121-33-5 ]
  • [ 61032-42-6 ]
Reference: [1] European Journal of Medicinal Chemistry, 2017, vol. 125, p. 245 - 254
[2] Patent: CN105884699, 2016, A,
  • 8
  • [ 2426-87-1 ]
  • [ 61032-42-6 ]
Reference: [1] European Journal of Medicinal Chemistry, 2017, vol. 125, p. 245 - 254
[2] Patent: CN105884699, 2016, A,
  • 9
  • [ 27883-60-9 ]
  • [ 61032-42-6 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 18, p. 5342 - 5346
  • 10
  • [ 111627-40-8 ]
  • [ 61032-42-6 ]
Reference: [1] ChemMedChem, 2016, vol. 11, # 20, p. 2327 - 2338
  • 11
  • [ 61032-42-6 ]
  • [ 155666-33-4 ]
Reference: [1] Organic Letters, 1999, vol. 1, # 11, p. 1835 - 1837
[2] Chemical Communications, 2016, vol. 52, # 87, p. 12869 - 12872
  • 12
  • [ 61032-42-6 ]
  • [ 162364-72-9 ]
Reference: [1] Tetrahedron Letters, 2011, vol. 52, # 10, p. 1053 - 1056
[2] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 18, p. 5342 - 5346
[3] European Journal of Medicinal Chemistry, 2017, vol. 125, p. 245 - 254
[4] Patent: CN105541736, 2016, A,
[5] Patent: CN105884699, 2016, A,
[6] Patent: WO2006/117552, 2006, A1,
  • 13
  • [ 61032-42-6 ]
  • [ 162012-72-8 ]
Reference: [1] Patent: US2014/235634, 2014, A1,
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 61032-42-6 ]

Aryls

Chemical Structure| 155666-33-4

[ 155666-33-4 ]

2-Amino-4-(benzyloxy)-5-methoxybenzoic acid

Similarity: 0.98

Chemical Structure| 1609073-29-1

[ 1609073-29-1 ]

2-Amino-4,5-bis((4-methoxybenzyl)oxy)benzoic acid

Similarity: 0.98

Chemical Structure| 179688-27-8

[ 179688-27-8 ]

Ethyl 2-amino-4,5-bis(2-methoxyethoxy)benzoate

Similarity: 0.97

Chemical Structure| 401568-70-5

[ 401568-70-5 ]

Methyl 2-amino-4-hydroxybenzoate

Similarity: 0.89

Chemical Structure| 6705-03-9

[ 6705-03-9 ]

2-Amino-5-methoxybenzoic acid

Similarity: 0.89

Ethers

Chemical Structure| 155666-33-4

[ 155666-33-4 ]

2-Amino-4-(benzyloxy)-5-methoxybenzoic acid

Similarity: 0.98

Chemical Structure| 1609073-29-1

[ 1609073-29-1 ]

2-Amino-4,5-bis((4-methoxybenzyl)oxy)benzoic acid

Similarity: 0.98

Chemical Structure| 179688-27-8

[ 179688-27-8 ]

Ethyl 2-amino-4,5-bis(2-methoxyethoxy)benzoate

Similarity: 0.97

Chemical Structure| 6705-03-9

[ 6705-03-9 ]

2-Amino-5-methoxybenzoic acid

Similarity: 0.89

Chemical Structure| 379228-26-9

[ 379228-26-9 ]

Methyl 2-amino-4,6-dimethoxybenzoate

Similarity: 0.87

Esters

Chemical Structure| 179688-27-8

[ 179688-27-8 ]

Ethyl 2-amino-4,5-bis(2-methoxyethoxy)benzoate

Similarity: 0.97

Chemical Structure| 401568-70-5

[ 401568-70-5 ]

Methyl 2-amino-4-hydroxybenzoate

Similarity: 0.89

Chemical Structure| 379228-26-9

[ 379228-26-9 ]

Methyl 2-amino-4,6-dimethoxybenzoate

Similarity: 0.87

Chemical Structure| 706792-04-3

[ 706792-04-3 ]

Methyl 3-amino-5-ethoxybenzoate

Similarity: 0.86

Chemical Structure| 1646152-47-7

[ 1646152-47-7 ]

Methyl 5-methoxy-4-((4-methoxybenzyl)oxy)-2-nitrobenzoate

Similarity: 0.84

Amines

Chemical Structure| 155666-33-4

[ 155666-33-4 ]

2-Amino-4-(benzyloxy)-5-methoxybenzoic acid

Similarity: 0.98

Chemical Structure| 1609073-29-1

[ 1609073-29-1 ]

2-Amino-4,5-bis((4-methoxybenzyl)oxy)benzoic acid

Similarity: 0.98

Chemical Structure| 179688-27-8

[ 179688-27-8 ]

Ethyl 2-amino-4,5-bis(2-methoxyethoxy)benzoate

Similarity: 0.97

Chemical Structure| 401568-70-5

[ 401568-70-5 ]

Methyl 2-amino-4-hydroxybenzoate

Similarity: 0.89

Chemical Structure| 6705-03-9

[ 6705-03-9 ]

2-Amino-5-methoxybenzoic acid

Similarity: 0.89